Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
08:17am, Friday, 20'th Dec 2024
Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped The post Novo Nordisk Dives On CagriSe
Novo Nordisk to explore CagriSema weight-loss potential in new trial
07:55am, Friday, 20'th Dec 2024
Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting disappoint
Novo Nordisk A/S - share repurchase programme
07:47am, Friday, 20'th Dec 2024
Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and
Novo Nordisk's new weight-loss drug works better, but not as well as expected
07:39am, Friday, 20'th Dec 2024
Novo Nordisk's stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
06:58am, Friday, 20'th Dec 2024
On Friday, Novo Nordisk A/S NVO stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.
Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results
06:28am, Friday, 20'th Dec 2024
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.
Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar.
06:20am, Friday, 20'th Dec 2024
The experimental obesity drug CagriSema disappointed investors.
Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected
05:51am, Friday, 20'th Dec 2024
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, sending i
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
05:41am, Friday, 20'th Dec 2024
Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety tr
Novo Nordisk Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal
04:21pm, Thursday, 19'th Dec 2024
Novo has handed Wolff one of the most complex jobs in all of pharmaceuticals.
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
06:15am, Thursday, 19'th Dec 2024
One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relativ
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
10:38am, Wednesday, 18'th Dec 2024
Recent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 ago
Novo Holdings completes $16.5 bln takeover of Catalent
09:08am, Wednesday, 18'th Dec 2024
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfill
Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this case an undisclosed cardiometabolic target Total potential
Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug
06:15am, Wednesday, 18'th Dec 2024
When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for w
